Clinical Trial Update: A First in Human Study of AL-611 in Healthy Volunteers and Patients With Hepatitis C Virus Infection [Phase 1]

View source ↗

Summary

A first-in-human Phase 1 study of AL-611 in healthy volunteers and patients with Hepatitis C has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis C

Drugs mentioned

• AL-611

Snippet

Sponsor: Alios Biopharma Inc. | Conditions: Hepatitis C | Phase 1 | Status: TERMINATED